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Abstract
Background: Recent autopsy studies found microvascular rarefaction in remodeled myocardium of patients who
died of heart failure with preserved ejection-fraction (HFpEF). This condition has not been investigated so far by
non-invasive methods in patients with HFpEF. The aim was to quantify the intravascular volume (IVV) compartment
by CMR in HFpEF patients.
Methods: In two separate CMR examinations, HFpEF patients (n = 6; 12 examinations) and post-myocardial infarction
patients (post-MI; n = 6; 12 examinations) were studied with T1-mapping (MOLLI-sequence) before and after IV bolus of
0.03mmol/Kg of the intravascular contrast-medium (CM) Gadofosveset and 0.2 mmol/Kg of the extravascular CM
Gadobutrol yielding IVV and extracellular volume (ECV), respectively. Healthy controls (n = 10 with Gadofosveset only, n
= 10 with Gadobutrol only) were also studied with the same protocol. IVV and ECV were measured in the basal septum
(without ischemic scar in post-MI patients). In post-MI patients, ECV and IVV were also measured in the ischemic scar.
Left ventricular (LV) volumes, mass, and ejection-fraction were measured by standard protocol. LV global longitudinal
strain (GLS) was calculated by feature tracking on long-axis cine acquisitions.
Results: LV mass to end-diastolic volume ratio and GLS in HFpEF were higher and lower, respectively, than in healthy
controls and post-MI patients, whereas the post-MI patients showed lower LV ejection-fraction. Compared to healthy
myocardium of controls, IVV in scar was reduced (0.135 ± 0.018 vs 0.109 ± 0.008, respectively, p = 0.005), while ECV was
increased (0.244 ± 0.037 vs 0.698 ± 0.106, respectively, p < 0.001). However, IVV did not differ among HFpEF, post-MI,
and healthy controls (0.155 ± 0.033, 0.146 ± 0.038, and 0.135 ± 0.018, respectively, p = 0.413), whereas ECV was higher in
HFpEF than in post-MI and healthy controls (0.304 ± 0.159, 0.270 ± 0.017, and 0.244 ± 0.037, respectively, p = 0.003).
Conclusions: The T1-mapping technique combined with an intravascular CM shows potential to measure IVV. In infarct
scar with substantially increased ECV, IVV was significantly reduced. Unlike in infarct scar, in remodeled myocardium of
HFpEF patients, increased ECV was not accompanied by a reduction of IVV.
Introduction
Heart failure with preserved ejection fraction (HFpEF) is a
common condition with increasing prevalence and high
morbidity and mortality [1, 2] HFpEF occurs in associ-
ation with advanced age, cardiovascular and metabolic co-
morbidities as well as with a pro-inflammatory state [2]. It
is characterized by impaired left ventricular (LV)
relaxation and increased diastolic stiffness [2, 3]. Despite
intensive research, the myocardial abnormalities subtend-
ing HFpEF are incompletely understood. Studies of endo-
myocardial biopsy or of autopsy of selected HFpEF
patients reported myocyte hypertrophy, diffuse interstitial
fibrosis and signs of systemic and myocardial inflamma-
tion [4, 5]. In this setting microvasculature rarefaction was
also observed, and it was inversely correlated to myocar-
dial fibrosis [6, 7]. Accordingly, the detection and quantifi-
cation of microvascular rarefaction might be of great value
for assessing the pathophysiological abnormalities
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occurring in patients with HFpEF and for establishing its
diagnosis. However, the non-invasive measurement of
myocardial intravascular compartment in humans is
challenging.
Based on these premises, we developed a cardiac mag-
netic resonance (CMR)-based approach for the quantifica-
tion of the myocardial intravascular volume (IVV)
consisting in the use of an intravascular gadolinium-based
contrast medium (CM) combined with the quantitative
measurement of myocardial T1 by currently available
mapping technique [8, 9]. To this end, we administered an
intravascular and extravascular CM 1). in healthy controls,
2). in HFpEF patients with LV hypertrophy (LVH) and/or
proven interstitial myocardial fibrosis, and 3). in patients
with chronic myocardial infarctions (MI). Post-MI pa-
tients were included to study the remote non-infarcted
myocardium, which typically undergoes remodelling pro-
cesses with eccentric hypertrophy [10]. In addition, in
post-MI patients, we tested the hypothesis that the intra-
vascular CM allows to quantify the reduced IVV, which is
a typical feature of post-ischemic infarct scar [11].
Methods
Study population
Twenty healthy controls without cardiovascular risk fac-
tors, 6 HFpEF patients and 6 patients with previous MI
were enrolled into the study. The healthy controls were
recruited through local advertising and had no history or
symptoms of cardiovascular disease and no cardiovascu-
lar risk factors. Patients were recruited from the clinical
database of our CMR center after having performed a
clinically-indicated CMR examination using an extravas-
cular CM (Gadobutrol, Gadovist®, Bayer Healthcare,
Germany). HFpEF patients were selected according to
the following criteria: 1) LV-EF > 40% and presence of
left ventricular hypertrophy (LVH) and/or T1-mapping
based extracellular volume fraction (ECV) > 28%, [8]; 2)
dyspnea (unless physical activity was compromised by
peripheral arterial disease); 3) history of arterial hyper-
tension and ≥ 1 additional cardiovascular risk factor. Ex-
clusion criteria were myocardial ischemia and/or
previous MI (by clinical history and on CMR) or known
significant valvular heart disease. Post-MI patients were
selected on the basis of previous MI (> 12months) and
chronic fibrotic infarct scar on post-contrast CMR. In
this subgroup, the scar did not involve the basal inter-
ventricular septum. Extensive validation of the T1-map-
ping technique has been performed with regard to
standardization of the method [12–14] and in compari-
son to histopathology when combined with an extracel-
lular Gd-based CM to measure ECV [15]. In this study,
we aimed to expand the T1 mapping technique to meas-
ure the distribution volume of an intravascular CM in
order to obtain IVV non-invasively. Accordingly, ECV
and IVV were measured by the administration of the
extravascular CM gadovist and the intravascular CM
gadofosveset (Ablavar®, Lantheus Medical Imaging, US),
respectively. In the controls, the two CMs were adminis-
tered in two separate groups of 10 controls each (to
avoid 2 CM administrations in the same subject accord-
ing to the Local Ethic Committee recommendation).
Post-MI and HFpEF patients were studied in a second
research-dedicated CMR examination with the adminis-
tration of the intravascular CM.
The study complied with the Declaration of Helsinki
and all examinations were conducted at the Lausanne
University Hospital after obtaining the approval from
local ethics committee. All study participants provided
written informed consent.
Cardiac magnetic resonance protocol
In the extravascular CMR protocol, i.e. in the clinical
CMR examination, cine SSFP images were acquired for
functional LV evaluation, followed by pre-contrast
T2-map and T1-map acquisitions at the basal short-axis
position. At ≥15-min after the i.v. bolus administration of
0.20mmol/kg of the extracellular CM gadobutrol, the
T1-map was re-acquired at the same short-axis basal pos-
ition. Then, late gadolinium enhancement (LGE) imaging
was performed on short axis covering the entire LV.
In the intravascular CMR protocol, cine SSFP and
T2-map and native T1-maps were acquired as in the extra-
cellular CMR protocol. Then, at 3min after the i.v. bolus
administration of 0.03mmol/kg of the intravascular CM
gadofosveset, the T1-map was re-acquired at the same
basal short-axis slice position. The 3-min interval was
chosen to allow for a homogeneous distribution of the
intravascular CM in the subjects’ blood pool, i.e. in the
intravascular compartment. This protocol was performed
in all patients (6 HFpEF and 6 post-MI patients) and in 10
healthy controls (as described above). In the extravascular
and intravascular CMR protocol, hematocrit was mea-
sured immediately before CMR.
All studies were performed on a 1.5 Tesla system
(Siemens Healthcare, Aera Magnetom, Erlangen,
Germany) using dedicated cardiac software, a
32-channel phased array receiver coil, and ECG trig-
gering. The pulse sequence parameters for functional
cine SSFP, T1- and T2-mapping as well as for the
LGE imaging are given in Table 1.
Image analysis
The formula-1 below was applied to calculate the CM
distribution volume after administration of the
extra-cellular and intravascular CM yielding extracel-
lular volume (ECV) and intravascular volume (IVV),
respectively [8].
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Distribution volume ¼ 1−hematocritð Þ
 1=T1myo−postð Þ− 1=T1myo−preð Þ
1=T1blood−postð Þ− 1=T1blood−preð Þ
T1-myo-pre and T1-blood-pre indicate myocardial and
blood native T1 values, respectively, and T1-myo-post and
T1-blood-post indicate the T1 values of myocardium and
blood pool after CM administration, respectively.
ECV and IVV were measured 1). in normal myocar-
dium of controls, i.e. in the basal septum; 2). in the basal
septum of HFpEF patients, and 3). in the basal septum
(=non-infarcted myocardium) and in the infarcted
(=LGE positive) myocardium of the post-MI patients
(Fig. 1). The interstitial space was calculated as the dif-
ference between ECV and IVV.
All studies were saved in DICOM format and analyzed
by 1 operator with > 10 years experience in CMR using
GTVolume software (GyroTools™, Version 2.2.1, Zurich,
Switzerland). For all maps acquired in the basal short-axis,
a region of interest (ROI) was manually drawn in the
mid-layer of the interventricular septum (segment 2 and 3
according to AHA segmentation). The ROI was drawn by
leaving 2mm from each endocardial side to avoid partial
volume contamination with blood pool signal. On
T1-maps, a second ROI was manually traced in the LV
cavity avoiding papillary muscles and trabeculas. These
myocardial and blood pool pre-contrast ROIs were then
copied to the post-contrast T1-maps. Additionally, for
post-MI patients (n = 6), another ROI was drawn in the in-
farcted region in the native and corresponding
post-contrast T1-maps. For a correct identification of the
fibrotic scar on the T1-maps, a careful side-by-side
comparison between T1-maps and LGE images was per-
formed. In LGE positive patients the scar mass was quan-
tified as myocardium with a signal intensity exceeding the
mean signal intensity of remote myocardium by >6SD
using a semi-automatic algorithm [16] and expressed as
mass (g) or as percentage of LV mass (%).
Feature tracking analysis
Two-dimensional Cardiac Performance Analysis Software
(TomTec, Munich, Germany) was used to obtain global
LV longitudinal strain derived as the mean between longi-
tudinal strain obtained in 2-chamber, 3-chamber, and
4-chamber cine data sets. The mathematical assumptions
used and the clinical validation of the feature tracking
technology have been previously described [17]. After the
upload of the CMR images on a dedicated workstation,
the endocardial border of the LV was manually traced in
the end-diastolic frame and the software automatically
propagated the contour and followed its features through-
out the remainder of the cardiac cycle.
Statistical analysis
Continuous variables are expressed as mean value ± SD
and categorical variables are expressed as frequency and
(%). Continuous variable differences across healthy con-
trols, HFpEF, and post-MI patients were analyzed by
ANOVA, and followed by Bonferroni’s post hoc analyses
when required. Categorical variable differences across
the groups were assessed by Chi-squared, or by Fisher’s
exact test if the expected cell count was < 5. Differences
in p value < 0.05 were considered statistically significant.
All analyses were performed using SSPS version 21
(SPSS, Chicago, Ill-US).
Table 1 CMR pulse sequence parameters
Tecnique Sequence Parameters Notes on Image Generation
Cine imaging Breath-hold segmented steady
state free precession
flip angle:56°; voxel size: 1,4 × 1,4 × 6,0
TR/TE:37,1/1,19 ms, matrix: 256 × 208; field-of-
view: 300 × 240 mm2; parlallel imaging acquisi-
tion technique: 2; cardiac phases: 25
T1-mapping 2D Breath-hold MOdified Look-
Locker Inversion-Recovery (MOLLI)
Acquisition Sampling Scheme:
a) pre-contrast (native): 5 (3)3
b) Post-contrast: 4 (1)3 (1)2
Read-out: SSFP single-shot, trigger delay in
mid-diastole, flip angle: 35°, voxel size: 1.5 ×
1.5x8mm3; parallel acquisition factor: 2, number
of inversion pulse 2 and 3 for native and post-
contrast
Generation of inline motion corrected pixel-
based T1-maps by acquiring a series of images
over several heart-beats with shifted inversion
delays corrected by RR duration
T2-mapping 2D Breath-hold T2-prepared SSFP
sequence
Read-out: single-shot SSFP, trigger delay in
mid-diastole, flip angle: 70°, voxel size: 1.9 ×
1.9x8mm3, matrix size: 192 × 154;; FOV:
360x288mm2, parlallel imaging acquisition
technique: 2
Generation of inline motion corrected pixel-
based T2-maps by acquiring 3 images with dif-
ferent T2 preparation time (0, 25, 55 ms) with a
gap of 2 RR interval within 1 breath-hold
Late
gadolinium
enhancement
2D breath-hold segmented T1-
weighted gradient echo inversion
recover with phase sensative
reconstraction
Flip angle: 35°; voxel size: 1,3 × 1,3 × 8 mm3;
matrix size; 256 × 208; TR.TE:848/3,8 ms; FOV:
340 × 275 mm2; parallel acquisition factor 2,
number of segment: 20 to 30
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Results
Characteristics of healthy controls and patients
The baseline characteristics of the healthy controls and
patients are summarized in Table 2. Healthy controls
were younger and did not have risk factors as compared
to patients. For CMR characteristics, LV volumes did
not differ significantly across the groups, whereas LV-EF
was consistently lower in patients with previous MI than
in healthy controls. In the HFpEF group, LV-EF was pre-
served with 58 ± 10% [18] with only 1 patient with a
LV-EF < 50%, i.e. 48%). LV mass and the ratio between
LV mass and LV end-diastolic volume were greater in
the HFpEF group than in controls and post-MI patients.
Distribution volume of intravascular CM in normal
myocardium and post-MI scar tissue
In healthy controls, by applying formula-1, a low distribu-
tion volume in the myocardium of 0.135 ± 0.018 was ob-
tained after intravascular CM administration, reflecting the
IVV of normal myocardium. In the scar tissue of post-MI
patients, IVV was reduced as compared to healthy controls
(0.109 ± 0.008 vs 0.135 ± 0.018, p = 0.005; (Fig. 2a) likely
representing the well-known microvascular rarefication in
scar tissue, a hallmark of dense fibrotic tissue [11]. The op-
posite was found for ECV, which was massively elevated in
the scar tissue in comparison to normal healthy myocar-
dium (0.698 ± 0.106 vs 0.244 ± 0.037, p < 0.001; Fig. 2b).
Distribution volume of intra- and extravascular CM in
non-infarcted myocardium of healthy controls and
patients
Native T1 value of the myocardium was slightly lower in
controls than in HFpEF or post-MI patients, whereas na-
tive T1 of blood and hematocrit were comparable among
groups (Table 2). The IVV of the basal septum did not dif-
fer between healthy controls, post-MI and HFpEF patients
(Table 2, Fig. 2c. By pooling the IVV data of the basal
septum of post-MI and HFpEF patients (n = 12), IVV of
the basal septum tended to be higher in patients than in
healthy controls (0.151 ± 0.034 vs 0.135 ± 0.018, p = 0.216).
On the other hand, ECV of the basal septum was signifi-
cantly increased in HFpEF and post-MI patients as com-
pared to the controls (0.301 ± 0.052 vs 0.276 ± 0.023 vs
0.231 ± 0.029, respectively, over-all p < 0.001, Fig. 2d).
Fig. 1 Native and post-contrast T1-maps in healthy volunteers, HFpEF, and post-MI patients. First and second rows, basal short-axis native (a, d),
post-gadofosveset (b), post-gadobutrol (e) T1-maps and LGE image (c, f) in two healthy volunteers. The region-of-interest (ROI) was traced within
the basal interventricular septum in all volunteers and patients. Third and fourth rows, in HFpEF and post-MI patients, respectively, show basal
short-axis native (g, l), post-gadofosveset (h, m), post-gadobutrol (I, n) T1-maps, and LGE images (k, o). In the HFpEF patient (third row), non-
ischemic scars (red arrow in K) was included in the septal ROI for the calculation of IVV and ECV. In post-MI patients (bottom row), a second ROI
was traced within the ischemic scar taking as reference the LGE image (o, with red arrows indicating the scar)
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The T2 values of the septum tended to be higher in
HFpEF than post-MI patients or controls (Table 2),
but were within the upper normal range (48.0 ms) de-
fined as mean plus 2 standard deviations in the
pooled data of the healthy controls (n = 20, T2 = 44.6
± 1.7 ms).
Discussion
The main findings of the current study can be summa-
rized as follows. First, in patients with HFpEF, there was
no reduction of the myocardial intravascular compart-
ment as derived by T1-mapping after gadofosveset ad-
ministration, while the extracellular compartment was
expanded as compared to controls. Second, in the scar
tissue of post-MI patients the intravascular compartment
was significantly reduced, while the extracellular com-
partment was massively increased. Third, myocardial
edema was not detected in the remodeled myocardium
of HFpEF patients as evidenced by the normal T2 values.
By assuming that the vascular endothelium is not per-
meable to albumin under normal conditions, gadofosve-
set, which binds reversibly to albumin, behaves
preferentially as an intravascular CM after intravenous
bolus injection. Using T1-mapping, we calculated the
relaxivity of myocardium and blood pool immediately,
i.e. at 3 min, after gadofosveset bolus injection, and these
measurements, in conjunction with the hematocrit, were
used to derive the myocardial IVV by adopting the pre-
viously published formula [9, 11]. The IVV was signifi-
cantly decreased in the myocardial scar of post-MI
patients as compared to normal myocardium of healthy
controls, indicating that this approach is able to detect a
reduced intravascular space, which is a key feature of
dense fibrotic scar [11]. When estimating IVV by the
Table 2 Baseline characteristics and CMR results
Variable Volunteer Gadofesveset
(n = 10)
Volunteer Gadobutrol
(n = 10)
HFpEF
Patients
(n = 6)
Post-MI
Patients
(n = 6)
Overall
p-value
Agea 35 ± 15 36 ± 11 69 ± 10 58 ± 13 < 0.001
BMI 23 ± 1 24 ± 3 26 ± 3 27 ± 3 0.099
Gender (male) n, % 7 (70) 7 (70) 5 (83) 4 (67) 0.771
Dyspnea (%)e n.a n.a 4 (67%) 0 (0) 0.014
Symptomtic PAD n.a n.a 2 (33%) 0 (0)
Hypertension n, (%) n.a n.a 6 (100) 5 (83) 0.296
Hypercholesterolemia n, (%) n.a n.a 4 (67) 3 (50) 0.558
Active Smoking n, (%) n.a n.a 4 (67) 3 (50) 0.557
Family for CAD n, (%) n.a n.a 1 (17) 1 (17) NA
Diabetes n (%) n.a n.a 2 (33) 0 (0) 0.455
LVEDVI (ml/m2) 87 ± 14 84 ± 10 79 ± 16 95 ± 16 0.247
LVESVI (ml/m2) 33 ± 7 33 ± 5 44 ± 26 52 ± 17 0.064
LVEF (%)d 63 ± 6 61 ± 12 58 ± 10 46 ± 11 0.002
LVMI (g/m2)b 60 ± 11 61 ± 17 85 ± 11 73 ± 16 0.009
LVM/LVEDVc, b 0.70 ± 11 0.72 ± 0,17 1.10 ± 0.15 0.77 ± 0.14 < 0.001
Global Longitudinal Strain (%)b −22.78 −21.52 −16.43 −17.07 0.015
Ischemic Scar n, (%)f n.a n.a n.a 6 (100) n.a
Ischemic Scar Extent (% LV mass) f n.a n.a n.a 8.4 ± 2.9 n.a.
Native T1 septum (ms)
a 1000 ± 19 989 ± 27 1028 ± 31 1029 ± 44 0.029
Native T1 blood (ms) 1568 ± 85 1601 ± 110 1607 ± 101 1474 ± 257 0.317
T2 septum (ms) 43.8 ± 1.4 45.3 ± 1.8 46.2 ± 1.0 44.7 ± 3.0 0.099
Hct 0.43 ± 0.04 0.043 ± 0.06 0.40 ± 0.06 0.43 ± 0.04 0.726
ECV septumb n.a. 0.244 ± 0.037 0.304 ± 0.0159 0.270 ± 0.017 0.003
IVV septum 0.135 ± 0.018 n.a. 0.155 ± 0.033 0.146 ± 0.038 0.413
Interstitial Space n.a n.a 0.149 ± 0.033 0.124 ± 0.044 0.281
aBonferroni post-hoc analysis with p < 0.05 between post-MI and HFpEF versus the controls; bBonferroni post-hoc analysis with p < 0.05 between HFpEF versus the
controls; cBonferroni post-hoc analysis with p < 0.05 between HFpEF versus post-MI patients; dBonferroni post-hoc analysis with p < 0.05 between post-MI patients
versus controls; 1 patient in the HFpEF group with EF < 50% (= 48%). epatients were limited by peripheral arterial disease; fScar on late gadolinium enhancement.
Hct: hematocrit; PAD: peripheral arterial disease
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administration of an intravascular CM, it is important to
recognize that T1-mapping measures the effect of CM
on proton relaxation, not reflecting directly the concen-
tration of CM in the intravascular compartment. Al-
though gadofosveset is a prevalently intravascular CM, it
affects the extravascular compartment by proton (i.e.
water) exchange across the vascular wall [19]. Several
studies suggested a slow exchange regime for the intra –
extravascular water [19]. Simulations and in-vivo mea-
surements by Donahue and co-workers also demon-
strated an increasing overestimation of IVV with
increasing intravascular CM dosages (i.e. with an in-
crease in pre-contrast to post-contrast difference of
blood relaxivity ΔR1). For the slow exchange model, sim-
ulations found an overestimation of IVV by approxi-
mately 10–30% at a ΔR1 of 9, which is matching the ΔR1
found in our study (at 3 min after gadofosveset injection)
[19]. After IV injection, ~ 70% of circulating gadofosve-
set binds reversibly to albumin resulting in an increase
in relaxivity by 5- to 10-fold (r1 = 25mmol
.L-1.s− 1) as
compared with the free fraction (r1 = 5 mmol
.L− 1.s− 1)
[20]. The unbound fraction of gadofosveset behaves as
an extra-vascular extra-cellular CM, thereby increasing
tissue relaxivity in the extravascular space and thus,
overestimating IVV. Although we acknowledge that our
protocol may lead to an overestimation of IVV by means
of either mechanisms mentioned above, it should be
kept in mind that overestimation is expected to occur
systematically across the diverse study groups and
should therefore not affect the trend of the observed
pathophysiological abnormalities (e.g., increase or de-
crease of IVV). Taking into account that the unbound
fraction of gadofosveset behaves as an extracellular
extravascular CM, the overestimation of IVV is expected
to be larger in those pathological conditions with an ex-
panded extracellular compartment (i.e. larger ECV).
Nevertheless, our approach showed an important de-
crease of IVV in the ischemic scar for which we mea-
sured a substantial expansion of the extracellular
compartment in the order of 70% using an extracellular
CM (ECV of 0.698 ± 0.106). Our results are in line with
a study by Prech and co-workers [11], who quantified
capillary density in autopsy hearts. In that study, in
post-MI patients, capillary density was reduced in
post-ischemic non-reperfused scar tissue by approxi-
mately 40% versus normal. In infarcted myocardium, we
found a reduction of IVV of about 25% versus normal,
i.e. less than that reported by Prech et al. [11]. This dif-
ference matches the expected slight overestimation of
10–30% by our method as discussed above. With this
reasoning, it follows that the unbound fraction of gado-
fosveset is very unlikely to contribute significantly to
IVV overestimation in HFpEF patients, who had only
slightly increased ECV as compared to healthy
Fig. 2 Top Panel: Bars and 95% confidence intervals of intravascular (IVV; a) and extracellular (ECV; b) volumes in healthy controls (green) and
ischemic scar (red). IVV was reduced and ECV was strongly augmented in the ischemic scar as compared to normal myocardium. Bottom Panel:
Bars and 95% confidence intervals of IVV (c) and ECV (d) in healthy (green), post-MI patients (remodeled myocardium not including the scar, light
blue) and HFpEF patients (blue). Bonferroni’s post-hoc analysis, † P < 0.05
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volunteers. In summary, we set out a non-invasive CMR
approach to estimate IVV by measuring T1-maps before
and at 3 min after intravascular CM bolus injection,
which was demonstrated in ischemic scar versus normal
myocardium of healthy controls. Reduced IVV of
chronic ischemic scar is well established in the literature,
and our approach was capable to correctly gauge this
key feature of dense chronic fibrotic scar.
When applying the IVV measurement to non-infarcted
myocardium, IVV was not reduced in HFpEF myocardium
or in non-infarcted myocardium of post-MI patients.
Hence, our results do not confirm some of the previous
studies in HFpEF [6, 7]. In particular, in an autopsy cohort
of 124 patients who died of HFpEF, Mohammed et al. re-
ported lower coronary microvascular density and more se-
vere fibrosis as compared to control subjects [6]. These
authors also found an inverse relationship between micro-
vascular density and fibrosis. However, in their study the
HFpEF cohort was somewhat heterogeneous being consti-
tuted by 37% of patients with a previous history of MI,
and as many as 74% of patients showed LV dilatation and
hypertrophy. On the other hand, in our study none of the
HFpEF patients had a history of coronary artery disease,
evidence of ischemia, or ischemic scar, and none was in
advanced stage of heart failure. Conversely, our results are
in line with the study by Prech and co-workers [11], who
quantified capillary density in autopsy hearts of post-MI
patients. In that study, capillary density in remote
non-infarcted myocardium was not different from normal
myocardium of control hearts.
While slow water exchange was addressed as a potential
confounder for measuring IVV in chronic fibrotic
post-ischemic scar, additional confounders should be con-
sidered when interpreting our IVV results for non-infarcted
remodeled myocardium. The concept of using an intravas-
cular CM to quantify IVV is strictly based on the assump-
tion that the intravascular CM does not leak into the
interstitial space. In the situation of an inflammatory state
of the microcirculation of remodeled myocardium as pro-
posed in the literature [2, 21], leaking intravascular CM
would cause overestimation of IVV, in particular, if one con-
siders the higher relaxivity of the albumin-bound fraction of
Gadofosveset. To minimize this effect, in the current study
T1 was measured at 3min. Post CM injection, as Pedersen
et al. [20] showed maximum effect of CM leakage occurring
at 30min post-injection in an animal model. Elevated myo-
cardial native, i.e. pre-contrast, T1 values result in elevated
IVV according the formula we used (page 5). Puntmann et
al. found elevated native T1 of viable myocardium of
post-MI patients [22] and hypertrophied myocardium [23],
which correlated with outcome [22]. In agreement with
these studies, we also found elevated native T1 values of
non-infarcted remodeled myocardium compared to con-
trols (see Table 2), and this elevated native T1 may
contribute to an increase in IVV. Furthermore, the type of
the T1 mapping pulse sequence may also influence the cal-
culated T1 and thus, distribution volumes. With the MOLLI
sequence we used, we were able to measure reduced IVV in
scar tissue (i.e. even in tissue with massively expanded
extracellular space) and in a recent study, this MOLLI se-
quence performed best in measuring ECV among a set of
different pulse sequences in comparison to histology [24].
While we did not observe differences in IVV between
healthy controls and HFpEF patients, ECV was expanded
in the later, which is very likely related to an accumulation
of extracellular matrix in the cardiac interstitium, since
myocardial edema was excluded by normal myocardial T2
values. Accordingly, our data on ECV, i.e. on interstitial fi-
brosis, are in line with other studies, which reported an
expanded ECV compared to healthy controls and which
correlated well with markers of HFpEF severity [15]. Thus,
this study is in line with others in quantifying ECV as a
measure of collagen accumulation, while the current
non-invasive approach to measure IVV could not detect a
rarefaction of the microvasculature of hypertrophied/re-
modeled myocardium.
Limitations
The small number of patients included represents an
important limitation. This was due to the fact that on
August 2016, the production of gadofosveset was
halted due to commercial reasons not permitting the
recruitment of further patients. Both, ECV and IVV
were not validated against endomyocardial biopsy.
Rarefaction of the microvasculature in scar tissue is
well established in the literature [11]. Therefore, it
was deemed adequate to use scar tissue as a reference
to demonstrate the feasibility of the proposed method
to detect reduced IVV in myocardium. While these
preliminary data indicate a potential use to probe
IVV and microvascular rarefication, the introduction
of new intravascular CM must be awaited to be able
to further test this approach and to finally assess its
potential clinical usefulness.
Conclusions
The proposed technique exploiting T1-mapping in com-
bination with the administration of an intravascular CM
is able to detect a reduction of the intravascular com-
partment in post-infarction scar tissue. However, our
study findings do not support the hypothesis of micro-
circulatory rarefication as a patho-mechanism in the
myocardium of HFpEF patients.
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